Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant alpha toxoid + recombinant Panton-Valentine leukocidin S subunit vaccine
- Development stage
- Unknown
- Lead developer
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is an investigational bivalent toxoid vaccine developed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). It is designed to prevent infections caused by *Staphylococcus aureus*, particularly those involving tissue-damaging toxins. The vaccine contains two recombinant protein components: a genetically detoxified version of alpha-hemolysin (recombinant alpha toxoid, rAT) and the S subunit of the Panton-Valentine leukocidin (rLukS-PV). By stimulating the production of neutralizing antibodies against these virulence factors, the vaccine aims to prevent toxin-mediated cell lysis and reduce the severity of skin and soft tissue infections as well as invasive staphylococcal disease. Its safety and immunogenicity were evaluated in a Phase 1/2 clinical trial (NCT01011335).
- Other names
- Bivalent S. aureus vaccinerAT/rLukS-PV vaccine
02
Targets
LukS-PV (Panton-Valentine leukocidin S component)Hla (Staphylococcus aureus alpha toxin)
Beyond the preview
Go deeper on recombinant alpha toxoid + recombinant Panton-Valentine leukocidin S subunit vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant alpha toxoid + recombinant Panton-Valentine leukocidin S subunit vaccine.